Literature DB >> 32071689

Utility of Physicochemical Properties for the Prediction of Toxicological Outcomes: Takeda Perspective.

Tomoya Yukawa1,2, Russell Naven1,2.   

Abstract

The role that physicochemical properties play toward increasing the likelihood of toxicity findings in in vivo studies has been well reported, albeit sometimes with different conclusions. We decided to understand the role that physicochemical properties play toward the prediction of in vivo toxicological outcomes for Takeda chemistry using 284 internal compounds. In support of the previously reported "3/75 rule", reducing lipophilicity of molecules decreases toxicity odds noticeably; however, we also found that the trend of toxicity odds is different between compounds classified by their ionization state. For basic molecules, the odds of in vivo toxicity outcomes were significantly impacted by both lipophilicity and polar surface area, whereas neutral molecules were impacted less so. Through an analysis of several project-related compounds, we herein demonstrate that the utilization of the 3/75 rule coupled with consideration of ionization state is a rational strategy for medicinal chemistry design of safer drugs.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32071689      PMCID: PMC7025387          DOI: 10.1021/acsmedchemlett.9b00536

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  30 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

Review 2.  Toxicology Strategies for Drug Discovery: Present and Future.

Authors:  Eric A G Blomme; Yvonne Will
Journal:  Chem Res Toxicol       Date:  2015-12-04       Impact factor: 3.739

3.  Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis.

Authors:  M Paul Gleeson
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

4.  Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.

Authors:  Tim Luker; Lilian Alcaraz; Kamaldeep K Chohan; Niklas Blomberg; Dearg S Brown; Roger J Butlin; Thomas Elebring; Andrew M Griffin; Simon Guile; Stephen St-Gallay; Britt-Marie Swahn; Steve Swallow; Michael J Waring; Mark C Wenlock; Paul D Leeson
Journal:  Bioorg Med Chem Lett       Date:  2011-07-27       Impact factor: 2.823

5.  Volume of Distribution in Drug Design.

Authors:  Dennis A Smith; Kevin Beaumont; Tristan S Maurer; Li Di
Journal:  J Med Chem       Date:  2015-04-01       Impact factor: 7.446

Review 6.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

Review 7.  The influence of lipophilicity in drug discovery and design.

Authors:  John A Arnott; Sonia Lobo Planey
Journal:  Expert Opin Drug Discov       Date:  2012-09-19       Impact factor: 6.098

8.  Lipophilicity in drug discovery.

Authors:  Michael J Waring
Journal:  Expert Opin Drug Discov       Date:  2010-03       Impact factor: 6.098

9.  Physicochemical determinants of human renal clearance.

Authors:  Manthena V S Varma; Bo Feng; R Scott Obach; Matthew D Troutman; Jonathan Chupka; Howard R Miller; Ayman El-Kattan
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

10.  Escape from flatland: increasing saturation as an approach to improving clinical success.

Authors:  Frank Lovering; Jack Bikker; Christine Humblet
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

View more
  2 in total

Review 1.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

2.  Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies.

Authors:  Joshua S Alford; John W Lampe; Dorothy Brach; Richard Chesworth; Kat Cosmopoulos; Kenneth W Duncan; Sean T Eckley; Jeffrey L Kutok; Alejandra Raimondi; Thomas V Riera; Brian Shook; Cuyue Tang; Jennifer Totman; Neil A Farrow
Journal:  ACS Med Chem Lett       Date:  2022-06-07       Impact factor: 4.632

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.